Yonatan Butbul Aviel1, Sameh Tatour2, Ruth Gershoni Baruch3, Riva Brik4. 1. Department of Pediatrics B, Meyer Children's Hospital, Rambam Medical Center, Haifa, Israel; Pediatric Rheumatology Service, Meyer Children's Hospital, Rambam Medical Center, Haifa, Israel; Rappaport Faculty of Medicine, Technion-lsrael Institute of Technology, Haifa, Israel. Electronic address: yonatanbutbul@gmail.com. 2. Department of Pediatrics B, Meyer Children's Hospital, Rambam Medical Center, Haifa, Israel; Rappaport Faculty of Medicine, Technion-lsrael Institute of Technology, Haifa, Israel. 3. Rappaport Faculty of Medicine, Technion-lsrael Institute of Technology, Haifa, Israel. 4. Department of Pediatrics B, Meyer Children's Hospital, Rambam Medical Center, Haifa, Israel; Pediatric Rheumatology Service, Meyer Children's Hospital, Rambam Medical Center, Haifa, Israel; Rappaport Faculty of Medicine, Technion-lsrael Institute of Technology, Haifa, Israel.
Abstract
OBJECTIVE: To evaluate the efficacy of colchicine in reducing the frequency of attacks in patients with PFAPA. STUDY DESIGN: We conducted a 6-month open label, randomized, controlled study among patients with PFAPA who attend the Pediatric Rheumatology Clinic at the Rambam Medical Center in Israel. A total of 18 patients aged4 -11 years (males:females ratio = 11:7) were randomized into a control group (I, 10 children) and a study group (II, 8 children). Group I was followed for 6 months without any intervention, and group II was initially followed for 3 months and was thereafter treated with colchicine for 3 additional months, according to standard regimen. During the 6-month period of the study the patients and their physician recorded all the episodes of PFAPA in a constructed log. DNA analyses for the 5 common FMF mutations in Israel were performed in 17 out of the 18 patients. RESULTS: The number of episodes during the first 3 months was similar in both groups (group I 3.2 ± 1.5, group II 4.9 ± 2.3; p ≤ 0.12). Group II had significantly less PFAPA attacks in the second period while on colchicine therapy (4.9 ± 2.3 vs. 1.6 ± 1.2; p ≤ 0.01), in opposition to group I, where no difference in the number of attacks was noted between the first and second period of follow-up (3.2 ± 1.5 vs. 2.7 ± 1.5; p = 0.33). Of the 17 patients tested, 8 were carriers for FMF mutations (2 in group I and 6 in group II). CONCLUSION:Colchicine prophylaxis seems to be effective in reducing the number of attacks in PFAPA.
RCT Entities:
OBJECTIVE: To evaluate the efficacy of colchicine in reducing the frequency of attacks in patients with PFAPA. STUDY DESIGN: We conducted a 6-month open label, randomized, controlled study among patients with PFAPA who attend the Pediatric Rheumatology Clinic at the Rambam Medical Center in Israel. A total of 18 patients aged4 -11 years (males:females ratio = 11:7) were randomized into a control group (I, 10 children) and a study group (II, 8 children). Group I was followed for 6 months without any intervention, and group II was initially followed for 3 months and was thereafter treated with colchicine for 3 additional months, according to standard regimen. During the 6-month period of the study the patients and their physician recorded all the episodes of PFAPA in a constructed log. DNA analyses for the 5 common FMF mutations in Israel were performed in 17 out of the 18 patients. RESULTS: The number of episodes during the first 3 months was similar in both groups (group I 3.2 ± 1.5, group II 4.9 ± 2.3; p ≤ 0.12). Group II had significantly less PFAPA attacks in the second period while on colchicine therapy (4.9 ± 2.3 vs. 1.6 ± 1.2; p ≤ 0.01), in opposition to group I, where no difference in the number of attacks was noted between the first and second period of follow-up (3.2 ± 1.5 vs. 2.7 ± 1.5; p = 0.33). Of the 17 patients tested, 8 were carriers for FMF mutations (2 in group I and 6 in group II). CONCLUSION:Colchicine prophylaxis seems to be effective in reducing the number of attacks in PFAPA.
Authors: Kalpana Manthiram; Suzanne C Li; Jonathan S Hausmann; Gil Amarilyo; Karyl Barron; Hanna Kim; Simona Nativ; Geraldina Lionetti; Andrew Zeft; Donald Goldsmith; David Kimberlin; Kathryn Edwards; Fatma Dedeoglu; Sivia Lapidus Journal: Rheumatol Int Date: 2017-03-07 Impact factor: 2.631
Authors: Cristian Quintana-Ortega; Elena Seoane-Reula; Laura Fernández; Marisol Camacho; Peter Olbrich; Olaf Neth; Sara Murias; Clara Udaondo; Agustín Remesal; Cristina Calvo; Rosa Alcobendas Journal: Eur J Rheumatol Date: 2020-09-18